tiprankstipranks
Advertisement
Advertisement

HK:3320 Stock Latest News

China Resources Pharmaceutical Completes First Tranche of 2026 PRC Bond Issuance
Company AnnouncementsChina Resources Pharmaceutical Completes First Tranche of 2026 PRC Bond Issuance
18d ago
China Resources Pharma Subsidiary Raises Up to RMB1 Billion in 2026 Bond Issue
PremiumCompany Announcements
China Resources Pharma Subsidiary Raises Up to RMB1 Billion in 2026 Bond Issue
19d ago
China Resources Pharmaceutical Delivers Higher Revenue and Profit in 2025
PremiumCompany Announcements
China Resources Pharmaceutical Delivers Higher Revenue and Profit in 2025
21d ago
China Resources Pharmaceutical Declares Final 2025 Dividend With Currency Option
PremiumCompany Announcements
China Resources Pharmaceutical Declares Final 2025 Dividend With Currency Option
21d ago
CR Sanjiu Posts Strong Asset and Revenue Growth, Boosts Dividend for 2025
PremiumCompany Announcements
CR Sanjiu Posts Strong Asset and Revenue Growth, Boosts Dividend for 2025
25d ago
CR Boya Revenue Rises but Profit Slumps as China Resources Pharma Unit Proposes Dividend
PremiumCompany AnnouncementsCR Boya Revenue Rises but Profit Slumps as China Resources Pharma Unit Proposes Dividend
25d ago
China Resources Pharma Subsidiary Dong-E-E-Jiao Lifts 2025 Profit and Proposes Higher Dividend
Premium
Company Announcements
China Resources Pharma Subsidiary Dong-E-E-Jiao Lifts 2025 Profit and Proposes Higher Dividend
26d ago
China Resources Pharma Subsidiary KPC Posts Profit Slump but Maintains Dividend
Premium
Company Announcements
China Resources Pharma Subsidiary KPC Posts Profit Slump but Maintains Dividend
26d ago
CR Double-Crane Grows Profit and Net Assets Despite Flat 2025 Revenue
PremiumCompany Announcements
CR Double-Crane Grows Profit and Net Assets Despite Flat 2025 Revenue
26d ago
CR Jiangzhong Lifts Profit and Dividend Despite Revenue Dip in 2025
PremiumCompany Announcements
CR Jiangzhong Lifts Profit and Dividend Despite Revenue Dip in 2025
26d ago
China Resources Pharmaceutical Plans Further Stake Sale in Tianmai Biotechnology
PremiumCompany Announcements
China Resources Pharmaceutical Plans Further Stake Sale in Tianmai Biotechnology
29d ago
China Resources Pharmaceutical Sets March Board Meeting on 2025 Results, Dividend Plan
PremiumCompany Announcements
China Resources Pharmaceutical Sets March Board Meeting on 2025 Results, Dividend Plan
1M ago
China Resources Pharma Unit to Invest RMB1.5 Billion in New Health Consumer Products Park
PremiumCompany AnnouncementsChina Resources Pharma Unit to Invest RMB1.5 Billion in New Health Consumer Products Park
2M ago
China Resources Pharma Launches RMB1.42 Billion Tender to Sell Tianmai Biotechnology Stake
Premium
Company Announcements
China Resources Pharma Launches RMB1.42 Billion Tender to Sell Tianmai Biotechnology Stake
2M ago
China Resources Pharmaceutical Shareholders Approve Sales Framework and New Articles at 2026 EGM
Premium
Company Announcements
China Resources Pharmaceutical Shareholders Approve Sales Framework and New Articles at 2026 EGM
2M ago
CR Sanjiu Posts Double-Digit Revenue Growth but Softer Profit Gains in 2025
PremiumCompany Announcements
CR Sanjiu Posts Double-Digit Revenue Growth but Softer Profit Gains in 2025
2M ago
Tasly Pharmaceutical Posts Higher 2025 Profit Despite Revenue Dip and Reliance on One-Off Gains
PremiumCompany Announcements
Tasly Pharmaceutical Posts Higher 2025 Profit Despite Revenue Dip and Reliance on One-Off Gains
2M ago
Subsidiary KPC Pharmaceuticals Warns of Sharp Profit Decline in 2025 Unaudited Results
PremiumCompany Announcements
Subsidiary KPC Pharmaceuticals Warns of Sharp Profit Decline in 2025 Unaudited Results
2M ago
CR Boya Warns of Profit Slump Despite Revenue Growth After Green Cross Acquisition
PremiumCompany Announcements
CR Boya Warns of Profit Slump Despite Revenue Growth After Green Cross Acquisition
2M ago
China Resources Pharma Subsidiary Wins CSRC Nod for RMB3 Billion Bond Programme
PremiumCompany AnnouncementsChina Resources Pharma Subsidiary Wins CSRC Nod for RMB3 Billion Bond Programme
3M ago
China Resources Jiangzhong Pharmaceutical Lifts 2025 Profit Despite Revenue Decline
Premium
Company Announcements
China Resources Jiangzhong Pharmaceutical Lifts 2025 Profit Despite Revenue Decline
3M ago
China Resources Pharmaceutical Calls 2026 EGM to Approve Sales Framework and New Articles
Premium
Company Announcements
China Resources Pharmaceutical Calls 2026 EGM to Approve Sales Framework and New Articles
3M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >